BIOMAT Database Logo BIOMAT Database Logo

Plasma catecholamines, neuropeptide Y and leucine-enkephalin in uremic patients before and after dialysis during rest and handgrip. 1998

M Klin, and M Waluga, and R Rudka, and A Madej, and M Janiszewska, and E Grzebieniak, and A Wesolowky
Department of Clinical Pharmacology, Division of Nephrology-Miners' Hospital, Bytom.

We have studied the effects of handgrip on plasma levels of catecholamines, neuropeptide Y (NPY), and leu-enkephalin before and after hemodialysis of uremic patients. A cuprophan dialyzer was used. We found, that dopamine level was higher in uremia group before hemodialysis both during rest (0.38 +/- 0.39 pmol/ml) and handgrip (1.13 +/- 1.00 pmol/ml) compared to control (0.17 +/- 0.19, and 0.66 +/- 0.83 pmol/ml respectively). Hemodialysis leads to further increase of its level (0.49 +/- 0.35 pmol/ml) at rest. Epinephrine level was almost the same in uremic patients before (0.43 +/- 0.51 pmol/ml) and after dialysis (0.46 +/- 0.60) as in control subjects (0.41 +/- 0.37 pmol/ml) during the rest. Its level measured after the handgrip was the highest in uremic group after dialysis (2.10 +/- 2.00 pmol/ml), significantly lower before dialysis (1.26 +/- 0.85 pmol/ml), and the lowest in control group (0.78 +/- 0.43 pmol/ml). Norepinephrine level were very similar in uremic group before dialysis (1.54 +/- 1.05 pmol/ml), after dialysis (1.79 +/- 1.29 pmol/ml) and in control group (1.46 +/- 1.06 pmol/ml) during the rest. During the handgrip test its level was higher in uremic group after hemodialysis than before it (adequate values 8.78 +/- 4.61 and 6.70 +/- 4.74 pmol/ml). The difference between uremia group before dialysis and control group did not reach significance. The level of NPY has the tendency to increase in uremic patients. Dialysis leads to following increase of its level, but the changes did not reach the significance both in rest and handgrip. Leu-enkephalin level was higher in uremic group (9.21 +/- 7.62 pmol/ml) compared to control (5.22 +/- 1.53 pmol/ml). We observed non-significant fall of this level after dialysis (6.79 +/- 4.76 pmol/ml). We found the same tendency during the handgrip, and the changes were significant. CONCLUSIONS uremia per se leads to increase the level of dopamine and leu-enkephaline during the rest and handgrip, but the level of epinephrine only during the handgrip; dialysis leads to further increase of dopamine during the rest, but epinephrine, norepinephrine and leu-enkephaline only during the handgrip.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D009478 Neuropeptide Y A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones. Neuropeptide Y-Like Immunoreactive Peptide,Neuropeptide Tyrosine,Neuropeptide Y Like Immunoreactive Peptide,Tyrosine, Neuropeptide
D012146 Rest Freedom from activity. Rests
D004743 Enkephalin, Leucine One of the endogenous pentapeptides with morphine-like activity. It differs from MET-ENKEPHALIN in the LEUCINE at position 5. Its first four amino acid sequence is identical to the tetrapeptide sequence at the N-terminal of BETA-ENDORPHIN. Leucine Enkephalin,5-Leucine Enkephalin,Leu(5)-Enkephalin,Leu-Enkephalin,5 Leucine Enkephalin,Enkephalin, 5-Leucine,Leu Enkephalin
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014511 Uremia A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms. Uremias

Related Publications

M Klin, and M Waluga, and R Rudka, and A Madej, and M Janiszewska, and E Grzebieniak, and A Wesolowky
Effects of clonidine on plasma catecholamines and neuropeptide Y in hypertensive patients at rest and during stress.
June 1993, Journal of cardiovascular pharmacology,
M Klin, and M Waluga, and R Rudka, and A Madej, and M Janiszewska, and E Grzebieniak, and A Wesolowky
Plasma catecholamines and vascular reactivity in uremic and dialysis patients.
January 1984, Contributions to nephrology,
M Klin, and M Waluga, and R Rudka, and A Madej, and M Janiszewska, and E Grzebieniak, and A Wesolowky
Plasma neuropeptide Y and catecholamines in pediatric patients undergoing cardiac operations.
February 1997, The Journal of thoracic and cardiovascular surgery,
M Klin, and M Waluga, and R Rudka, and A Madej, and M Janiszewska, and E Grzebieniak, and A Wesolowky
Plasma chromogranin A + B, neuropeptide Y and catecholamines in pheochromocytoma patients.
May 1991, Journal of internal medicine,
M Klin, and M Waluga, and R Rudka, and A Madej, and M Janiszewska, and E Grzebieniak, and A Wesolowky
Alpha-adrenoceptor influence on plasma levels of neuropeptide Y-like immunoreactivity and catecholamines during rest and sympathoadrenal activation in humans.
January 1988, Journal of cardiovascular pharmacology,
M Klin, and M Waluga, and R Rudka, and A Madej, and M Janiszewska, and E Grzebieniak, and A Wesolowky
Study of plasma neuropeptide Y (NPY) and catecholamines levels during spinal anesthesia.
June 1990, Ma zui xue za zhi = Anaesthesiologica Sinica,
M Klin, and M Waluga, and R Rudka, and A Madej, and M Janiszewska, and E Grzebieniak, and A Wesolowky
Study of plasma neuropeptide Y (NPY) and catecholamines levels during isoflurane anesthesia.
September 1990, Ma zui xue za zhi = Anaesthesiologica Sinica,
M Klin, and M Waluga, and R Rudka, and A Madej, and M Janiszewska, and E Grzebieniak, and A Wesolowky
[Respiratory function in uremic patients before and after dialysis].
May 1977, Minerva medica,
M Klin, and M Waluga, and R Rudka, and A Madej, and M Janiszewska, and E Grzebieniak, and A Wesolowky
Plasma immunoreactive neuropeptide Y in congestive heart failure at rest and during exercise.
October 1993, Scandinavian journal of clinical and laboratory investigation,
M Klin, and M Waluga, and R Rudka, and A Madej, and M Janiszewska, and E Grzebieniak, and A Wesolowky
Circulating neuropeptide Y in plasma from uremic patients consists of multiple peptide fragments.
January 1995, Peptides,
Copied contents to your clipboard!